tiprankstipranks
Advertisement
Advertisement

RCKT Stock Latest News

Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
Company AnnouncementsRocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
16h ago
8K
RCKT
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
PremiumThe Fly
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
16h ago
RCKT
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
9d ago
RCKT
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
PremiumCompany Announcements
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
23d ago
8K
RCKT
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
PremiumRatings
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
1M ago
RCKT
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
PremiumRatingsRocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
1M ago
RCKT
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
Premium
The Fly
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
1M ago
RCKT
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
Premium
Company Announcements
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
2M ago
8K
RCKT
Rocket Pharmaceuticals announces $180M sale of priority review voucher
PremiumThe Fly
Rocket Pharmaceuticals announces $180M sale of priority review voucher
2M ago
RCKT
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
PremiumCompany Announcements
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
2M ago
RCKT
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
2M ago
RCKT
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
PremiumRatings
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
2M ago
RCKT
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
PremiumThe FlyRocket Pharmaceuticals price target raised to $11 from $9 at Leerink
3M ago
RCKT
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
Premium
The Fly
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
3M ago
RCKT
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
Premium
The Fly
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
3M ago
RCKT
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
PremiumRatings
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
3M ago
RCKT
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
PremiumRatings
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
3M ago
RCKT
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
PremiumRatings
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
3M ago
RCKT
Video: Unity rises after better-than-expected pre-announcement
PremiumThe Fly
Video: Unity rises after better-than-expected pre-announcement
3M ago
U
AGX
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
PremiumCompany AnnouncementsRocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
3M ago
8K
RCKT
Rocket Pharmaceuticals announces FDA approval of Kresladi
Premium
The Fly
Rocket Pharmaceuticals announces FDA approval of Kresladi
3M ago
RCKT
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
Premium
Ratings
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
3M ago
RCKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >